Patients with tuberculosis and the AA genotype may be at an increased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.